The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)
Open accessAbstract
CONTEXT: Prostate-specific membrane antigen (PSMA) targeting positron emission tomography (PET) is emerging to become a reference imaging tool for the staging and restaging of patients with prostate cancer for both clinical routine and trials. The prostate cancer molecular imaging standardized evaluation (PROMISE) criteria have been proposed as a framework for whole-body staging (molecular imaging TNM staging, denoted miTNM staging) to describe the prostate cancer disease extent on PSMA-PET. OBJECTIVE: To create a comprehensive and integrated framework for PSMA-PET image interpretation and reporting. EVIDENCE ACQUISITION: We propose the PROMISE V2 framework, which integrates an updated miTNM system, improved assessment of local disease, and a slightly modified PSMA-expression score for clinical routine. We have added a response monitoring framework defining qualitative and quantitative parameters to be recorded for a longitudinal assessment in clinical trials. EVIDENCE SYNTHESIS: Lu-PSMA radioligand therapy. The proposed imaging parameters recorded for response assessment in clinical trials can be utilized to determine response according to PSMA-PET progression (PPP) or Response Evaluation Criteria in PSMA-PET/Computed Tomography (RECIP) frameworks, but also future response criteria. CONCLUSIONS: PROMISE V2 offers standardized reporting of disease extent for clinical routine and research. Parameters recorded within clinical trials facilitate objective response assessment. PATIENT SUMMARY: Prostate-specific membrane antigen (PSMA) targeting positron emission tomography (PET) has become a standard imaging examination for prostate cancer. We propose a comprehensive framework for the analysis and reporting of PSMA-PET findings that will improve the communication between imaging experts and uro-oncologists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864
Self-citationFendler, W. P., Calais, J., Eiber, M., Flavell, R. R., Mishoe, A., Feng, F. Y., Nguyen, H. G., Reiter, R. E., Rettig, M. B., Okamoto, S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0096 · Cited by 779
Self-citationEiber, M., Herrmann, K., Calais, J., Hadaschik, B., Giesel, F. L., Hartenbach, M., Hope, T., Reiter, R., Maurer, T., Weber, W. A., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.198119 · Cited by 626
Self-citationSimultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer
Eiber, M., Weirich, G., Holzapfel, K., Souvatzoglou, M., Haller, B., Rauscher, I., Beer, A. J., Wester, H.-J., Gschwend, J., Schwaiger, M., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.12.053 · Cited by 568
Self-citationHalabi, S., Kelly, W. K., Ma, H., Zhou, H., Solomon, N. C., Fizazi, K., Tangen, C. M., Rosenthal, M., Petrylak, D. P., Hussain, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.7270 · Cited by 461
Self-citationEmmett, L., Buteau, J., Papa, N., Moon, D., Thompson, J., Roberts, M. J., Rasiah, K., Pattison, D. A., Yaxley, J., Thomas, P., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.08.002 · Cited by 430
Self-citationPienta, K. J., Gorin, M. A., Rowe, S. P., Carroll, P. R., Pouliot, F., Probst, S., Saperstein, L., Preston, M. A., Alva, A. S., Patnaik, A., et al. (2021) · Journal of Urology · doi:10.1097/ju.0000000000001698 · Cited by 398
Self-citationMorris, M. J., Rowe, S. P., Gorin, M. A., Saperstein, L., Pouliot, F., Josephson, D., Wong, J. Y. C., Pantel, A. R., Cho, S. Y., Gage, K. L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4573 · Cited by 389
Self-citationE-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
Ceci, F., Oprea-Lager, D. E., Emmett, L., Adam, J. A., Bomanji, J., Czernin, J., Eiber, M., Haberkorn, U., Hofman, M. S., Hope, T. A., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05245-y · Cited by 368
Self-citation
Cited by
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer
Bakht, M. K., & Beltran, H. (2025) · Nature Reviews Urology · doi:10.1038/s41585-024-00900-z · Cited by 158
Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands
Naik, M., Khan, S. R., Lewington, V., Challapalli, A., Eccles, A., & Barwick, T. D. (2024) · British Journal of Radiology · doi:10.1093/bjr/tqae092 · Cited by 10
Metadata
- Authors
- Seifert, R., Emmett, L., Rowe, S. P., Herrmann, K., Hadaschik, B., Calais, J., Giesel, F. L., Reiter, R., Maurer, T., Heck, M., Gafita, A., Morris, M. J., Fanti, S., Weber, W. A., Hope, T. A., Hofman, M. S., Fendler, W. P., & Eiber, M.
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2023-05
- Volume
- 83
- Issue
- 5
- Pages
- 405-412
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W4327694432
- Cited by
- 313
- References
- 41
- FWCI
- 49.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). https://app.cochat.ai/papers/10.1016/j.eururo.2023.02.002
- The paper
- Seifert, R., Emmett, L., Rowe, S. P., Herrmann, K., Hadaschik, B., Calais, J., Giesel, F. L., Reiter, R., Maurer, T., Heck, M., Gafita, A., Morris, M. J., Fanti, S., Weber, W. A., Hope, T. A., Hofman, M. S., Fendler, W. P., & Eiber, M. (2023). Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). European Urology. https://doi.org/10.1016/j.eururo.2023.02.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.